Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab

Journal of Rheumatology

Volumn 38, Issue 12, 2011, Pages 2572-2580

  Taylor, Peter C ^a   Ritchlin, Christopher ^b   Mendelsohn, Alan ^c   Baker, Daniel ^c   Kim, Lilianne ^c   Xu, Zhenhua ^c   Mack, Michael ^c   Kremer, Joel ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Centocor Ortho Biotech Inc   (United States)

^d Center for Rheumatology LLP   (United States)

Author keywords

Anti tumor necrosis factor; Intravenous; Rheumatoid arthritis; Subcutaneous

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; GOLIMUMAB; METHOTREXATE; PLACEBO;

28 JOINT DISEASE ACTIVITY SCORE; ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; METHOTREXATE; PLACEBOS; SAFETY; TREATMENT OUTCOME;

EID: 82755162900     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110570     Document Type: Article

References (18)

1. Camussi G, Lupia E. The future role of anti tumor necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998;55:613-20. (Pubitemid 28203770)
2. Oppenheimer-Marks N, Lipsky PE. Adhesion molecules in arthritis: control of T cell migration into the synovium. In: Miossec P, van den Berg WB, Firestein GS, editors. T cells in arthritis. Basel, Switzerland: Birkhauser Verlag; 1998:129-48.
3. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-51.
4. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: Lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010;11:180-210.
5. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75. Erratum in: Arthritis Rheum 2010;62:3518. (Pubitemid 351563997)
6. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35. Erratum in: Ann Rheum Dis 2011;70:238-9.
7. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to TNF-α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96. Erratum in: Ann Rheum Dis 2011;70:238.
8. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21. Erratum in: Lancet 2009;374:1422. Comment in: Lancet 2009;374:178-80.
9. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Twenty-four week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86. Erratum in: Arthritis Rheum 2010;62:2555.
10. Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
11. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28. Erratum in: Arthritis Rheum 2010;62:3130.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
13. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
14. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
15. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60.
16. van Riel PL, van Gestel AM, Scott DL. EULAR handbook of clinical assessments in rheumatoid arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications B.V.; 2000:40.
17. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. (Pubitemid 10164318)
18. Ware JE Jr, Sherbourne CD. The MOS 36 item short form health survey (SF 36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.